Little House Capital LLC Has $2.36 Million Position in Amgen Inc. (NASDAQ:AMGN)

Little House Capital LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 4.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,313 shares of the medical research company’s stock after selling 357 shares during the period. Little House Capital LLC’s holdings in Amgen were worth $2,356,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Hershey Financial Advisers LLC bought a new stake in Amgen during the second quarter worth about $30,000. nVerses Capital LLC bought a new stake in Amgen during the second quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new stake in Amgen during the second quarter worth about $33,000. Matrix Trust Co bought a new position in shares of Amgen in the third quarter worth about $36,000. Finally, FSA Wealth Management LLC boosted its stake in shares of Amgen by 182.0% in the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 91 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Amgen stock traded down $4.07 during midday trading on Monday, reaching $317.59. The stock had a trading volume of 680,427 shares, compared to its average volume of 2,439,270. The firm’s 50-day moving average price is $326.07 and its 200 day moving average price is $312.41. Amgen Inc. has a 12 month low of $249.70 and a 12 month high of $346.85. The firm has a market capitalization of $170.37 billion, a PE ratio of 45.54, a P/E/G ratio of 2.86 and a beta of 0.61. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter in the prior year, the company earned $5.00 earnings per share. The company’s quarterly revenue was up 20.1% on a year-over-year basis. As a group, research analysts predict that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.83%. The ex-dividend date was Friday, August 16th. Amgen’s payout ratio is 128.57%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $320.00 to $335.00 in a research note on Wednesday, August 7th. Argus raised their price objective on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 price objective (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Cantor Fitzgerald assumed coverage on shares of Amgen in a report on Friday, September 27th. They issued an “overweight” rating and a $405.00 price objective for the company. Finally, Barclays raised their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.